Dose reference

Doses, monitoring and cautions

Starting doses and the monitoring that goes with them, for the medications geneticists are asked about most often. Open a card for the full dose sheet.

Calculate a dose by weight
Metabolic Recombinant acid alpha-glucosidase (GAA)

Alglucosidase alfa (Lumizyme)

Pompe disease, including infantile-onset disease.

20 mg/kg IV every 2 weeks.

Metabolic Urea cycle substrate

Arginine

Urea cycle disorders, to restore the arginine-dependent steps of the cycle.

150 mg/kg over 24 hours as a continuous infusion; maximum 250 mg/kg per day. A loading dose is not needed for short-term emergency use.

Metabolic Urea-cycle substrate

Arginine HCl IV

Urea-cycle disorders, to restore the arginine-dependent steps of the cycle.

Confirmed urea-cycle disorder: the cited label table lists 200 mg/kg for OTC/CPS1 and 600 mg/kg for ASS1/ASL, over 90-120 min, then the same dose over 24 hr.

Metabolic Urea cycle substrate (arginine supplement)

Arginine hydrochloride

Urea cycle disorders - argininosuccinate synthetase (citrullinemia) and argininosuccinate lyase (ASA) deficiencies; part of acute hyperammonemia manag

IV, for suspected urea cycle disorder: 200-300 mg/kg (as a 6% solution) over 90 minutes, then 200-300 mg/kg/day by continuous infusion. Oral arginine base: 400-700 mg/kg/day divided 3-4 times daily, a

Metabolic Medical formula

BCAA-free amino acid formula

Acute MSUD, to provide nitrogen and energy while branched-chain amino acids are withheld.

2-3.5 g/kg/day total protein equivalents in the cited inpatient regimen. Select the product, route and energy prescription with the metabolic dietitian.

Metabolic Water-soluble vitamin

Biotin

Biotinidase deficiency (profound and partial).

Profound biotinidase deficiency: 5-10 mg PO daily as a fixed daily dose. Partial deficiency: GeneReviews lists 2.5-10 mg PO daily, with practice variation.

Metabolic N-acetylglutamate analogue

Carglumic acid

Acute hyperammonaemia in NAGS deficiency and in propionic or methylmalonic acidaemia.

Acute NAGS deficiency: 100-250 mg/kg/day divided in 2-4 doses. Acute PA/MMA hyperammonaemia: 150 mg/kg/day if 15 kg or less; 3.3 g/m2/day if over 15 kg, given PO or enteral tube in 2 divided doses, co

Metabolic N-acetylglutamate synthase activator (NAGS cofactor analogue)

Carglumic acid (Carbaglu)

Hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency; adjunct in acute hyperammonemia of organic acidemias.

Oral, 100-250 mg/kg/day divided 2-4 times daily. Dissolve in water and give immediately; do not mix with hot liquids.

Metabolic Recombinant tripeptidyl peptidase 1 (TPP1)

Cerliponase alfa (Brineura)

CLN2 disease (late infantile neuronal ceroid lipofuscinosis).

Intraventricular every 2 weeks via a surgically implanted reservoir, followed by the labelled intraventricular electrolyte solution: birth to under 6 months 100 mg; 6 months to under 1 year 150 mg; 1

Metabolic Urea cycle substrate (citrulline supplement)

Citrulline

Proximal urea cycle disorders - carbamoyl phosphate synthetase I (CPS1) and ornithine transcarbamylase (OTC) deficiency.

Oral or NG, 170 mg/kg/day divided 3-4 times daily, increasing to 350-400 mg/kg/day as needed. Adjust to plasma amino acids.

Metabolic Carbohydrate and energy substrate

Dextrose 10% (D10)

Hypoglycaemia and reversal of catabolism in a metabolic crisis.

10% dextrose 2 mL/kg IV for severe hypoglycaemia under the pediatric emergency protocol, followed by a glucose infusion or appropriate feeds. D10 at 4.8 mL/kg/hr delivers 8 mg/kg/min. Calculate the ac

Metabolic Recombinant N-acetylgalactosamine-6-sulfatase (GALNS)

Elosulfase alfa (Vimizim)

Mucopolysaccharidosis type IVA (MPS IVA).

2 mg/kg IV once weekly.

Metabolic Recombinant arylsulfatase B

Galsulfase (Naglazyme)

Mucopolysaccharidosis type VI (MPS VI).

1 mg/kg IV once weekly.

Metabolic Vitamin B12 (cobalamin)

Hydroxocobalamin

Cobalamin-responsive methylmalonic acidaemia.

Suspected responsive methylmalonic acidaemia: 1 mg IM is a neonatal pathway initial dose. The stable-state responsiveness protocol uses 1 mg IM daily on 3 consecutive days with serial methylmalonate u

Metabolic Recombinant iduronate-2-sulfatase

Idursulfase (Elaprase)

Mucopolysaccharidosis type II (MPS II).

0.5 mg/kg IV once weekly.

Metabolic Recombinant acid beta-glucocerebrosidase

Imiglucerase (Cerezyme)

Gaucher disease types 1 and 3 (non-CNS manifestations).

2.5 units/kg IV three times weekly up to 60 units/kg IV every 2 weeks. Individualize by disease severity and treatment goals.

Metabolic Branched-chain amino acid

Isoleucine and valine

Acute MSUD, to replace the branched-chain amino acids that fall during treatment.

20-120 mg/kg/day each, enteral and/or parenteral under metabolic supervision, adjusted to measured amino acids and clinical response.

Metabolic Recombinant alpha-L-iduronidase

Laronidase (Aldurazyme)

Mucopolysaccharidosis type I (MPS I).

0.58 mg/kg IV once weekly.

Metabolic Carnitine supplement

Levocarnitine

Secondary carnitine deficiency in fatty-acid oxidation defects such as MCAD deficiency, and in organic acidaemias.

Oral: 100 mg/kg per day in 3 to 4 divided doses, up to 200 mg/kg per day in severe deficiency. Intravenous: 50 mg/kg per dose during acute decompensation.

Metabolic Carnitine supplement (promotes ester excretion)

Levocarnitine (L-carnitine)

Organic acidemias (methylmalonic and propionic acidemia) with secondary carnitine deficiency.

IV, during organic acidemia decompensation: 100 mg/kg/day as a continuous or divided infusion (up to 300-400 mg/kg/day in severe cases). Oral, 50-100 mg/kg/day divided 3-4 times daily.

Metabolic Carnitine supplement

Levocarnitine (organic acidaemias)

Methylmalonic and propionic acidaemia, to restore carnitine and clear acyl-CoA esters.

Example neonatal emergency pathway: 50 mg/kg IV or enteral loading, then 100 mg/kg/day IV or enteral, continuous or divided every 6-8 hr. Confirm with the metabolic team.

Metabolic Carnitine supplement

Levocarnitine (primary carnitine deficiency)

Primary carnitine deficiency.

Chronic targeted treatment: 100-200 mg/kg/day PO in 3 doses, titrated to plasma carnitine.

Metabolic 4-HPPD inhibitor

Nitisinone

Tyrosinemia type I (FAH deficiency).

Starting dose 0.5 mg/kg/dose PO twice daily. Titrate with the specialist per label, up to 2 mg/kg/day.

Metabolic Recombinant acid sphingomyelinase

Olipudase alfa (Xenpozyme)

Acid sphingomyelinase deficiency (ASMD) in patients aged 0-17 years.

For non-CNS manifestations, IV every 2 weeks with stepwise escalation in mg/kg: week 0 0.03, week 2 0.1, weeks 4 and 6 0.3, weeks 8 and 10 0.6, week 12 1, week 14 2, week 16 3. Continue 3 mg/kg IV eve

Metabolic Phenylalanine ammonia lyase (enzyme substitution)

Pegvaliase (Palynziq)

Phenylketonuria (PKU) in patients aged 12 years or older with blood phenylalanine above 600 micromol/L despite existing management.

Subcutaneous. Induction: 2.5 mg once weekly for 4 weeks. Titration: if tolerated, at least 1 week per step - 2.5 mg twice weekly, 10 mg once weekly, 10 mg twice weekly, 10 mg four times weekly, then 1

Metabolic Synthetic tetrahydrobiopterin cofactor

Sapropterin

BH4-responsive phenylketonuria, used alongside a phenylalanine-restricted diet to lower blood phenylalanine.

20 mg/kg orally once daily for the initial 4-week responsiveness trial. Maintenance 5 to 20 mg/kg once daily, guided by phenylalanine response.

Metabolic Recombinant lysosomal acid lipase

Sebelipase alfa (Kanuma)

Lysosomal acid lipase (LAL) deficiency.

Rapidly progressive disease presenting in the first 6 months of life: 1 mg/kg IV once weekly, increasing to 3 mg/kg weekly and then 5 mg/kg weekly if the response is suboptimal. Other pediatric patien

Metabolic Nitrogen scavenger (conjugates glycine to hippurate)

Sodium benzoate

Hyperammonemia in urea cycle disorders; given enterally for maintenance and intravenously with sodium phenylacetate for acute episodes.

Oral or NG, 250 mg/kg/day divided every 6 hours. IV (combined with sodium phenylacetate as Ammonul): 250 mg/kg loading dose over 90-120 minutes, then 250 mg/kg/day by continuous infusion.

Metabolic Nitrogen scavenger

Sodium benzoate

Urea cycle disorders, as part of nitrogen-scavenger therapy for hyperammonaemia.

250 to 500 mg/kg per day by mouth or infusion, combined with sodium phenylbutyrate as directed by metabolic medicine.

Metabolic Nitrogen scavenger

Sodium benzoate

Hyperammonaemia in urea cycle disorders (OTC and CPS deficiencies), to remove nitrogen by an alternative pathway.

Emergency: 250 mg/kg loading dose over 90 minutes, then 250 mg/kg over 24 hours as a continuous infusion; maximum 500 mg/kg per day.

Metabolic Nitrogen scavenger

Sodium phenylacetate + sodium benzoate IV

Hyperammonaemia in urea-cycle disorders (OTC, CPS1, NAGS, ASS1 and ASL deficiencies).

Each component: 250 mg/kg if 20 kg or less; 5.5 g/m2 if over 20 kg. Give the loading dose over 90-120 min, then the same amount of each over 24 hr. Dilute in D10 and use central access per label.

Metabolic Nitrogen scavenger

Sodium phenylbutyrate

Hyperammonaemia in urea cycle disorders (OTC and CPS deficiencies).

Emergency: 250 mg/kg loading dose over 90 minutes, then 250 mg/kg over 24 hours as a continuous infusion; maximum 500 mg/kg per day.

Metabolic Nitrogen scavenger

Sodium phenylbutyrate

Urea cycle disorders, to control hyperammonaemia alongside dietary protein restriction.

450 to 600 mg/kg per day by mouth or infusion, in 3 to 4 divided doses, adjusted to plasma ammonia and amino acids.

Metabolic Nitrogen scavenger (phenylacetate prodrug)

Sodium phenylbutyrate (Buphenyl, Pheburane)

Chronic maintenance of urea cycle disorders once acute hyperammonemia is under control; adjunct nitrogen-scavenger therapy.

Oral or NG, divided 4-6 times daily with feeds. Neonates and infants: up to 450-600 mg/kg/day (maximum 11.9 g/m2/day). Older children: 450-600 mg/kg/day (maximum 19.8 g/day). Titrate to plasma ammonia

Metabolic Brain-penetrant iduronate-2-sulfatase (enzyme replacement)

Tividenofusp alfa-eknm (Avlayah)

Neurologic manifestations of mucopolysaccharidosis II (Hunter syndrome) in pediatric patients.

IV weekly escalation: 3 mg/kg for at least 4 weeks, then 7.5 mg/kg for at least 4 weeks, then 15 mg/kg weekly as maintenance if tolerated. Follow the label for transition from idursulfase.

Metabolic Recombinant beta-glucuronidase (enzyme replacement)

Vestronidase alfa (Mepsevii)

Mucopolysaccharidosis VII (Sly syndrome).

4 mg/kg IV every 2 weeks.